镰状细胞贫血患儿接种麻疹疫苗后接受羟基脲治疗的血清学保护
本研究基于TREAT试验的回顾性队列,评估镰状细胞贫血(SCA)患儿接种麻疹疫苗后的抗麻疹血清保护(IgG≥200 IU/L)。结果显示,首剂后94%(33/35)、第二剂后92%(46/50)的患儿达到血清保护;
要点
- 多数SCA患儿接种麻疹疫苗后可达血清保护,比例与一般人群相近。
- 第二剂接种时年龄较大与血清保护 odds 降低独立相关。
- 羟基脲治疗不降低血清保护,早期启用反而与更高保护相关。
核心结论
- 大多数镰状细胞贫血患儿接种麻疹疫苗后可获得 adequate 血清保护,与一般人群相似。
- 及时接种和早期羟基脲治疗与更高的血清保护相关。
研究设计与样本
- 回顾性队列研究,纳入TREAT试验中登记的镰状细胞贫血患儿。
- 评估第一剂和 second 麻疹疫苗后的抗麻疹血清保护(ELISA法IgG≥200 IU/L)。
主要发现
- 第一剂后33/35(94%)达到血清保护。
- 第二剂后46/50(92%)达到血清保护。
关键数值与推荐
- 血清保护定义为抗麻疹IgG≥200 IU/L(ELISA法)。
临床怎么用
- SCA患儿应按计划接种麻疹疫苗以获取足够保护。
- 不必因羟基脲治疗而延迟或回避麻疹疫苗接种。
- 早期启用羟基脲可能有助于提升麻疹疫苗血清保护。
局限性
- 回顾性队列设计,可能存在残余混杂。
- 样本来自TREAT试验人群,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Children with sickle cell anemia (SCA) may have decreased antibody responses after some routine vaccines, but it is not known whether this affects the response to measles vaccination. It is critical to determine whether children with SCA develop adequate seroprotection after measles vaccination considering the rise in measles infections in the United States and persistent transmission globally, particularly in regions with high SCA prevalence. It is also unknown whether concurrent hydroxyurea treatment affects the measles antibody response to vaccination. We conducted a retrospective cohort study of children with SCA enrolled in the TREAT trial to determine antimeasles seroprotection (immunoglobulin G of ≥200 IU/L via enzyme-linked immunosorbent assay) after first and second measles vaccine (MV1 and MV2, respectively). Seroprotection was reached by 33 of 35 children (94%) after MV1 and by 46 of 50 (92%) after MV2. Each additional year of age at MV2 was associated with decreased odds of seroprotection (odds ratio [OR], 0.25; P = .02). Hydroxyurea treatment at the time of vaccination did not reduce seroprotection; rather, earlier hydroxyurea initiation was associated with increased seroprotection (OR, 4.4; P = .02). Most children with SCA are adequately protected after measles vaccination, similar to the general population, and seroprotection is increased with timely vaccination and early hydroxyurea treatment. This trial was registered at www.clinicaltrials.gov as NCT02286154.
引用
- Power-Hays A, Kincaid A, McElhinney KE, et al. Seroprotection after measles vaccination in children with sickle cell anemia receiving hydroxyurea. Blood Adv. 2026. PMID: 42448315. doi:10.1182/bloodadvances.2026019674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。